Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.

abstract：:We evaluated the activity and toxicity of two sequences of taxol combined with vinorelbine in disseminated malignant melanoma, metastatic beyond regional lymph nodes. Fifteen previously untreated patients, nine males and six females (median age 56 years), were enlisted between May 1994 and February 1995. Eight patient...

journal_title：Anti-cancer drugs

authors： Retsas S,Mohith A,Mackenzie H

更新日期：1996-02-01 00:00:00

abstract：:We carried out a detailed comparative study of the pharmacokinetics and toxicity of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) after high-dose intravenous methotrexate (HD-MTX) in children with acute lymphoblastic leukemia (ALL). Overall, 65 children were treated with 5 g/m2/24 h MTX and 88 children were...

journal_title：Anti-cancer drugs

authors： Csordas K,Hegyi M,Eipel OT,Muller J,Erdelyi DJ,Kovacs GT

更新日期：2013-02-01 00:00:00

abstract：:Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

journal_title：Anti-cancer drugs

authors： Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

更新日期：2016-06-01 00:00:00

abstract：:Single-agent docetaxel induces a response in 21-42% of patients with recurrent squamous cell cancer of the head and neck (SCCHN). When used in combination with 5-fluorouracil (5-FU), response rates (RRs) of between 24 and 27% have been reported. In contrast, in combination with cisplatin, docetaxel has achieved a RR o...

journal_title：Anti-cancer drugs

authors： Posner MR

更新日期：2001-02-01 00:00:00

abstract：:Fibroblast growth factor-inducible 14 (Fn14) has been reported to play an oncogene role in many types of cancer. However, its biological functions in small-cell lung cancer (SCLC) remain unknown. The aim of this study is to investigate the roles of Fn14 in the cell growth and chemoresistance of SCLC and its possible m...

journal_title：Anti-cancer drugs

authors： Li X,Zhu W,Chen Z,Luo L,Huang J,Zhang F,Li M,Guo Y,Guo L

更新日期：2014-11-01 00:00:00

abstract：:The immunotherapy significantly improved survival of non-small cell lung cancer patients, but it may cause immune-related adverse events, which are severe in less than 10% of cases. We report the case of one patient who developed myositis and myasthenia during nivolumab treatment for metastatic lung squamous carcinoma...

journal_title：Anti-cancer drugs

authors： Veccia A,Kinspergher S,Grego E,Peterlana D,Berti A,Tranquillini E,Caffo O

更新日期：2020-06-01 00:00:00

abstract：:Previously, we synthesized a series of hydrazide class of compounds and examined their cytotoxicity in a number of cancer cell lines. Among these analogues, SC144 exhibited potent cytotoxicity against a panel of drug-sensitive and drug-resistant cancer cell lines. To further explore its therapeutic potentials in the c...

journal_title：Anti-cancer drugs

authors： Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N

更新日期：2009-06-01 00:00:00

abstract：:Imatinib mesylate is a specific inhibitor of the Bcr-Abl protein tyrosine kinase that competes with ATP for its specific binding site in the kinase domain. It has activity against platelet-derived growth factor receptor alpha and beta (PDGFR-alpha and -beta), and c-kit, the receptor for stem cell factor. We have used ...

journal_title：Anti-cancer drugs

authors： Knight LA,Di Nicolantonio F,Whitehouse PA,Mercer SJ,Sharma S,Glaysher S,Hungerford JL,Hurren J,Lamont A,Cree IA

更新日期：2006-07-01 00:00:00

abstract：:Derivatives of bis-aryl urea have been widely investigated for their various biological activities, such as antiviral, anti-inflammatory and antiproliferative. We evaluated a new chemical entity consisting of bis-aryl urea moiety, N69B, for its anticancer activities and explored their underlying molecular mechanism. T...

journal_title：Anti-cancer drugs

authors： Wu J,Huang Y,Xie Q,Zhang J,Zhan Z

更新日期：2020-06-01 00:00:00

abstract：:The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

journal_title：Anti-cancer drugs

authors： Saikali Z,Singh G

更新日期：2003-11-01 00:00:00

abstract：:The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

journal_title：Anti-cancer drugs

authors： Medeiros KA,Joanitti GA,Silva LP

更新日期：2014-03-01 00:00:00

abstract：:The cytotoxic activity of bendamustine hydrochloride was evaluated against human ovarian and breast carcinoma cell lines including cell lines resistant to cisplatin and doxorubicin in vitro. The relative degree of resistance to bendamustine hydrochloride was lower in all cell lines compared with cyclophosphamide, melp...

journal_title：Anti-cancer drugs

authors： Strumberg D,Harstrick A,Doll K,Hoffmann B,Seeber S

更新日期：1996-06-01 00:00:00

abstract：:The aim of this study was to investigate in a randomized trial the activity of perioperative chemotherapy in patients treated with preoperative chemotherapy for locally advanced breast cancer and to compare it with the preoperative chemotherapy alone. Patients with cT2-3 N0-2 M0 histologically proven breast cancer, wi...

journal_title：Anti-cancer drugs

authors： Rocca A,Peruzzotti G,Ghisini R,Viale G,Veronesi P,Luini A,Intra M,Pietri E,Curigliano G,Giovanardi F,Maisonneuve P,Goldhirsch A,Colleoni M

更新日期：2006-11-01 00:00:00

abstract：:Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressiv...

journal_title：Anti-cancer drugs

authors： Colucci G,Giotta F,Gebbia V,Riccardi F,Pezzella G,Durini E,Caruso M,Romito S,Gebbia N

更新日期：1997-03-01 00:00:00

abstract：:Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

journal_title：Anti-cancer drugs

authors： He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

更新日期：2009-10-01 00:00:00

abstract：:Intensive cisplatin and oral etoposide for relapsed epithelial ovarian cancer (EOC), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all patients with relapsed EOC treated on the VDB protocol at the Cambridge Gynae-Oncology Cent...

journal_title：Anti-cancer drugs

authors： Gounaris I,Iddawela M,Parkinson C,Pratt J,Hatcher H,Basu B,Tan LT,Brenton JD,Earl HM

更新日期：2016-03-01 00:00:00

abstract：:A toxicology study of DENSPM was carried out in rats by multiple (once daily for 5 days) intravenous injection. Doses of 12.5, 25 and 50 mg DENSPM/kg were well tolerated. Infusion of 100 mg DENSPM resulted in distressing physical signs, including labored breathing, convulsive movements and acute death. There were no e...

journal_title：Anti-cancer drugs

authors： Kanter PM,Bullard GA,King JM

更新日期：1994-08-01 00:00:00

abstract：:Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxi...

journal_title：Anti-cancer drugs

authors： Cascinu S,Graziano F,Cardarelli N,Marcellini M,Giordani P,Menichetti ET,Catalano G

更新日期：1998-04-01 00:00:00

abstract：:Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

journal_title：Anti-cancer drugs

authors： Ma W,Liu X,Du W

更新日期：2019-02-01 00:00:00

abstract：:5-Fluorouracil, usually in combination with folinic acid, is widely used in the treatment of both colorectal and head and neck squamous cell cancer patients. Since 5-fluorouracil plus folinic acid and the antifolate thymidylate synthase inhibitor; raltitrexed have distinct mechanisms of action and toxicity profiles, w...

journal_title：Anti-cancer drugs

authors： Avallone A,Di Gennaro E,Bruzzese F,Laus G,Delrio P,Caraglia M,Pepe S,Comella P,Budillon A

更新日期：2007-08-01 00:00:00

abstract：:Antibody-cytokine fusion proteins (also called 'immunocytokines') represent an emerging class of biopharmaceutical products, which are being considered for cancer immunotherapy. When used as single agents, pro-inflammatory immunocytokines are rarely capable of inducing complete and durable cancer regression in mouse m...

journal_title：Anti-cancer drugs

authors： Corbellari R,Nadal L,Villa A,Neri D,De Luca R

更新日期：2020-09-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of symptoms and extension of life. A substantial body of evidence has eme...

journal_title：Anti-cancer drugs

authors： Nicum S,Cullen MH

更新日期：2000-09-01 00:00:00

abstract：:The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 p...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Lamont A,Hindley AC,Love S,TCA Ovarian Cancer Trial Group.

更新日期：2007-10-01 00:00:00

abstract：:The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a mechanism able to modify ErbB2 expression enhances the antitumor effect of trastuzumab. We analyzed whether granulocyte-colony stimulating factor (G-CSF), widely used...

journal_title：Anti-cancer drugs

authors： Cavalloni G,Sarotto I,Pignochino Y,Gammaitoni L,Migliardi G,Sgro L,Piacibello W,Risio M,Aglietta M,Leone F

更新日期：2008-08-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine is not clinically used to treat cancer because of toxicity, it exerts antiproliferative effects through the inhibition o...

journal_title：Anti-cancer drugs

authors： Kumar A,Sharma PR,Mondhe DM

更新日期：2017-03-01 00:00:00

abstract：:The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pretreated with cispla...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Buthaud X,Gross M,Bleuzen P,Cvitkovic E,Voinea A,Jasmin C,Romain D,Misset JL

更新日期：1999-03-01 00:00:00

abstract：:Large (>6 microm) rigid microparticles (MPs) become passively entrapped within the lungs after intravenous (i.v.) injection making them an attractive and highly efficient alternative to inhalation for pulmonary delivery. In this study, PEGylated 6 microm polystyrene MPs with multiple copies of the norvaline (Nva) alph...

journal_title：Anti-cancer drugs

authors： Chao P,Deshmukh M,Kutscher HL,Gao D,Rajan SS,Hu P,Laskin DL,Stein S,Sinko PJ

更新日期：2010-01-01 00:00:00

abstract：:The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

journal_title：Anti-cancer drugs

authors： Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

更新日期：2017-09-01 00:00:00

abstract：:The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

journal_title：Anti-cancer drugs

authors： Abe A,Yamada H

更新日期：2009-06-01 00:00:00